Eli Lilly and Company / Asahi Kasei Pharma

Chronic pain (P2X7 receptor antagonist for inflammatory and neuropathic pain)

51.6M US cases/yr · $79.0B Global pain management drug market 2021 (USD MM) · 560000 US chronic pain economic burden (USD MM annually)

Disease Overview

Chronic pain — defined as pain persisting >3 months — affects an estimated 51.6 million US adults (20.9%) per the 2021 CDC National Health Interview Survey, with high-impact chronic pain (limiting work or life activity) affecting 17.1 million US adults (6.9%). Subtypes include osteoarthritis (~32 million US adults), chronic low back pain (~16 million), neuropathic pain including diabetic peripheral neuropathy and post-herpetic neuralgia (~10 million), fibromyalgia (~4 million), inflammatory pain in rheumatoid arthritis (~1.3 million) and cancer pain. The economic burden of chronic pain in the US was estimated at $560-635 billion annually (NIH, IOM 2011, inflation-adjusted). Standard-of-care pharmacotherapy includes acetaminophen, NSAIDs (ibuprofen, naproxen, COX-2 selective celecoxib), tramadol, opioids (oxycodone, hydrocodone, morphine), gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants, SNRIs (duloxetine, milnacipran), topical agents (lidocaine, capsaicin), and procedural interventions (steroid injections, radiofrequency ablation, spinal cord stimulation). The opioid crisis (>100,000 US overdose deaths annually since 2021) created acute regulatory and commercial pressure for non-opioid analgesics. The 2021-2024 pipeline included NaV1.7/1.8 sodium channel inhibitors (Vertex VX-548 / suzetrigine, Biogen vixotrigine), CGRP antagonists (Ajovy, Aimovig, Emgality, Vyepti, Nurtec, Qulipta — primarily migraine), NGF antagonists (Tanezumab — Pfizer/Lilly discontinued 2021), TRPV1, P2X7 antagonists and others. Vertex's suzetrigine (NaV1.8) became the first new non-opioid pain mechanism approved in decades (Jan 2025).

Competitive Landscape

At deal date (Feb 2021), the non-opioid chronic pain pipeline was dominated by sodium channel inhibitors and a long tail of mechanism-of-action experimental approaches, with multiple late-stage failures in NGF and P2X7 spaces. P2X7 receptor antagonists target ATP-mediated activation of the inflammasome and IL-1β release in microglia and macrophages — proposed mechanism in inflammatory and neuropathic pain. Prior P2X7 programs included AstraZeneca's AZD9056 (Phase 2 in rheumatoid arthritis, terminated 2008 for inadequate efficacy), Pfizer's CE-224535 (Phase 2 RA, terminated 2010), GSK's GSK1482160 (Phase 1, discontinued), Janssen JNJ-54175446 (Phase 1/2 in major depressive disorder), Janssen JNJ-55308942 and Roche RO5545965 (Phase 1 CNS). Asahi Kasei's AK1780 was differentiated as orally bioavailable with CNS penetration and was developed for both inflammatory and neuropathic pain. Competing non-opioid pain mechanisms in development at deal date: Vertex VX-150 (NaV1.8, Phase 2, repurposed to suzetrigine VX-548 in 2022), Biogen vixotrigine (NaV1.7, Phase 3 trigeminal neuralgia), Pfizer/Lilly tanezumab (anti-NGF, CRL March 2021 after osteoarthritis Phase 3 program), Regeneron/Teva fasinumab (anti-NGF, Phase 3 OA), Centrexion CNTX-4975 (TRPV1 agonist, Phase 3 OA), Hydra Biosciences/Lilly TRP modulators, and Adynxx Inc. APN-110. The Lilly portfolio entering 2021 included Cymbalta (duloxetine, post-LOE), Lyrica/pregabalin via Pfizer prior, and the cebranopadol (NMR/MOR partial agonist) program from prior Forest/Allergan acquisition.